Key result
The CASZ1 locus (rs12046278) was significantly associated with apparent treatment-resistant hypertension risk compared to normotensive controls (OR 0.71; 95% CI 0.6-0.8; P=1.5×10-9).
Why the study?
Only a handful of genetic discovery efforts in apparent treatment-resistant hypertension had been described.
Population
Persons treated for hypertension from 10 European ancestry and 5 African ancestry cohorts
Comparison
Apparent treatment-resistant hypertension cases vs normotensive or treatment-responsive controls
Design
Case-control genome-wide association study and meta-analysis
Authors
Loading...
CASZ1 association supports genetic contribution to apparent treatment-resistant hypertension; leaves open clinical utility pending replication.
Case-Control (n=24,932)
Yes
Odds Ratio: 0.71 (95% CI 0.6–0.8)
p-value: p=1.5 × 10-9
A genome-wide association study identified the known hypertension locus CASZ1 as a risk locus for apparent treatment-resistant hypertension.
Irvin et al. (2019) conducted a case-control in Apparent treatment-resistant hypertension (aTRH) (n=24,932). CASZ1 locus (rs12046278) vs. Normotensive controls was evaluated on Apparent treatment-resistant hypertension (OR 0.71, 95% CI 0.6-0.8, p=1.5 × 10-9). The CASZ1 locus (rs12046278) was significantly associated with apparent treatment-resistant hypertension risk compared to normotensive controls (OR 0.71; 95% CI 0.6-0.8; P=1.5×10-9).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: